As AI takes a more prominent space in our lives and workplaces, it's essential that we protect our cognitive real estate (and ...

Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.

Catarina Craveiro, a biomedical research technician from Lisbon, had been hobbled by lower back pain from scoliosis since ...

The following is a summary of “A systematic review and meta-analysis of the response to placebo in clinical trials of ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...

The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The FDA has expanded the approval of Odactra to include treatment of house dust mite-induced allergic rhinitis in pediatric patients aged 5 to 11 years.

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...